Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure

Natriuretic Peptides in the Regulation of Cardiovascular Physiology and Metabolic Events

“…The trial was stopped early because of the overwhelming benefit of LCZ696. Combined angiotensin receptor blockade and neprilysin inhibition by LCZ696 significantly reduced the risk of hospitalization for HF and the number of deaths for cardiovascular causes 117. Importantly, no major safety concerns of the combination emerged during the study.…”

Atrial remodelling in heart failure: recent developments and relevance for heart failure with preserved ejection fraction

“…Similarly, increasing the levels of natriuretic peptides, e.g. with neprilysin inhibition, has had beneficial effects on LA size in HFrEF106 and in HFpEF [Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT trial107)] independent of the drug's blood‐pressure‐lowering effects 108. Lowering heart rate could improve atrial contribution to LV filling in HF.…”

Use of sacubitril/valsartan in acute decompensated heart failure: a case report

“…To our knowledge, this is the first reported use of sacubitril/valsartan for this indication. Sacubitril/valsartan was shown to be superior to enalapril in reducing mortality and HF hospitalizations in patients with chronic HFrEF 5. Sacubitril/valsartan also demonstrated fewer rates of inodilator agents (31% risk reduction) and MCS or HT (22% risk reduction) 7.…”

“…The angiotensin receptor blocker–neprilysin inhibitor, sacubitril/valsartan, is a novel therapy that can increase levels of endogenous vasoactive peptides 3, 4. Compared with enalapril, sacubitril/valsartan reduced the composite endpoint of cardiovascular death or HF hospitalization and is recommended as an alternative for angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers in patients with chronic HF with reduced ejection fraction (HFrEF) and New York Heart Association class II–III symptoms 5, 6. We report a case of stage D HFrEF weaned off continuous inodilator support using sacubitril/valsartan after failed attempts using standard therapies.…”